In an era where speed, precision, and innovation are redefining the boundaries of science, Tailored Genes, a Toronto-Based Viral vector manufacturer, is stepping into its next chapter of growth, one that could reshape the future of gene therapy manufacturing in Canada.
CEO Chetan Tailor founded Tailored Genes in 2014. His professional career in viral vector manufacturing makes him an industry expert. His dedication to science and his clients and his commitment to quality with full transparency makes Tailored Genes a great partner for viral vector manufacturing projects.
Founded on a promise to provide high-quality, custom viral vectors to the biotech and academic community, Tailored Genes has long been a quiet force in gene therapy. But with the success of funding to develop their new, state-of-the-art facility in Vaughan, Ontario, the company is no longer staying quiet. They are scaling up, and signaling that Canada is ready to lead.
A Facility That Reflects the Future
The new space is more than a physical expansion. It represents a philosophical shift for Tailored Genes, from an R&D-focused service provider to a full-service biomanufacturing partner, capable of guiding clients from concept to clinic.
The facility will be purpose-built with GMP (Goods Manufacturing Practice) readiness at its core. It will house cutting-edge technologies with scalable bioreactors designed for large-volume, clinical-grade viral vector production. These aren’t just upgrades, they’re the necessary tools to meet the moment biotech is in.
But what truly sets Tailored Genes apart is its uncompromising commitment to quality. Every vector produced is backed by rigorous quality control standards, and every ingredient, from enzymes to reagents, are acquired from top quality producers, with a focus to maintain North American sourced ingredients. There are no shortcuts. No mystery suppliers. Just full transparency and complete reliability.
“We’ve always focused on quality, but this facility allows us to take that even further,” said Dr. Chetan Tailor, founder of Tailored Genes. “We’re not just scaling up, we’re doubling down on purity, speed, and service. Our clients trust us with the most critical parts of their research, and we take that seriously.”
This elevated focus on quality is not only a point of pride, it’s a necessity. In a space where reproducibility, regulatory alignment, and clinical readiness are everything, Tailored Genes delivers viral vectors that exceed average industry benchmarks.
“In this field, you don’t get a second chance to get it right,” said Dr. Tailor. “We’ve designed our processes to be rock solid, from materials to methods to turnaround. There is no room for compromise.”
According to recent data, the global viral vector manufacturing market is projected to grow at a CAGR of over 18% through 2028, driven by the rising demand for gene therapies and cell-based treatments. Tailored Genes’ expansion aligns with this trajectory and puts them at the forefront of what many see as the next wave of precision medicine.
The Right Place at the Right Time
Positioned close to Vaughan Metropolitan subway station, just outside Toronto, the facility places Tailored Genes in the heart of a rapidly growing life sciences corridor. Proximity to major universities, research hospitals, and biotech startups means more than convenience—it means collaboration. It means being present and available in a way global competitors simply can’t replicate.
This facility also makes a bold statement: North American-based manufacturing matters. In a global supply chain where access and timelines can change overnight, Tailored Genes is anchoring its promise of reliability in Canadian soil.
“We’re proud that everything we produce, from start to finish, is done right here in North America,” said Dr. Tailor. “That’s important to our clients, especially as they face increasing regulatory scrutiny and global uncertainty.”
What This Means for Clients and the Industry
For biotech companies, academic researchers, and clinical developers, the message is clear: Tailored Genes is ready to scale with you. The new facility offers:
- Increased viral vector production capacity
- Faster project timelines, without sacrificing quality
- Integrated support from R&D through to preclinical and clinical readiness
- Uncompromised, North American-sourced manufacturing inputs
“We’re entering a new era where Canadian biotech can stand shoulder-to-shoulder with global leaders,” Dr. Tailor added. “Being one of the first to invest in full-service gene therapy manufacturing in Vaughan shows our commitment, not just to our clients, but to the future of life sciences in this country.”
This is more than growth. It’s a signal to the market that Canada is stepping forward, not only as a hub of innovation but as a place where scalable, world-class biomanufacturing can thrive.
As the life sciences sector continues to accelerate, infrastructure like Tailored Genes’ new facility will be essential. It will be where breakthroughs are manufactured, not just imagined.
And it all starts here.
